MX2022016422A - Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. - Google Patents
Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.Info
- Publication number
- MX2022016422A MX2022016422A MX2022016422A MX2022016422A MX2022016422A MX 2022016422 A MX2022016422 A MX 2022016422A MX 2022016422 A MX2022016422 A MX 2022016422A MX 2022016422 A MX2022016422 A MX 2022016422A MX 2022016422 A MX2022016422 A MX 2022016422A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- glycolate oxidase
- disease
- treatment
- oxidase inhibitors
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 3
- 108010062584 glycollate oxidase Proteins 0.000 title abstract 3
- 102100038837 2-Hydroxyacid oxidase 1 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 1
- 208000004777 Primary Hyperoxaluria Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
En este documento se describen compuestos, métodos para fabricar dichos compuestos, composiciones farmacéuticas y medicamentos que contienen dichos compuestos, y métodos para usar dichos compuestos para tratar o prevenir enfermedades o trastornos asociados con la enzima glicolato oxidasa (GO). Dichas enfermedades o trastornos incluyen, por ejemplo, trastornos del metabolismo del glioxilato, incluida la hiperoxaluria primaria, que están asociados con la producción de cantidades excesivas de oxalato.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762611995P | 2017-12-29 | 2017-12-29 | |
US201862765313P | 2018-08-20 | 2018-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022016422A true MX2022016422A (es) | 2023-01-30 |
Family
ID=65234672
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006414A MX2020006414A (es) | 2017-12-29 | 2018-12-28 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
MX2022016463A MX2022016463A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
MX2022016434A MX2022016434A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
MX2022016427A MX2022016427A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
MX2022016415A MX2022016415A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
MX2022016422A MX2022016422A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006414A MX2020006414A (es) | 2017-12-29 | 2018-12-28 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
MX2022016463A MX2022016463A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
MX2022016434A MX2022016434A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
MX2022016427A MX2022016427A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
MX2022016415A MX2022016415A (es) | 2017-12-29 | 2020-07-13 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. |
Country Status (17)
Country | Link |
---|---|
US (3) | US11384055B2 (es) |
EP (1) | EP3732167A2 (es) |
JP (2) | JP7344878B2 (es) |
KR (1) | KR20200112860A (es) |
CN (6) | CN111788187A (es) |
AR (1) | AR114070A1 (es) |
AU (1) | AU2018395275A1 (es) |
BR (1) | BR112020013073A2 (es) |
CA (1) | CA3086401A1 (es) |
CL (1) | CL2020001742A1 (es) |
IL (3) | IL297788A (es) |
MA (1) | MA51418A (es) |
MX (6) | MX2020006414A (es) |
PE (1) | PE20201500A1 (es) |
SG (1) | SG11202005807QA (es) |
TW (2) | TW202340155A (es) |
WO (1) | WO2019133770A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11384055B2 (en) * | 2017-12-29 | 2022-07-12 | Biomarin Pharmaceutical Inc. | Glycolate oxidase inhibitors for the treatment of disease |
WO2019165159A1 (en) | 2018-02-23 | 2019-08-29 | Oxalurx, Inc. | Compounds and methods for treating oxalate-related diseases |
SG11202012930RA (en) * | 2018-07-06 | 2021-01-28 | Orfan Biotech Inc | Triazole glycolate oxidase inhibitors |
CN114980886A (zh) * | 2019-08-22 | 2022-08-30 | 奥沙鲁克斯公司 | 用于治疗草酸盐相关疾病的化合物和方法 |
CA3155577A1 (en) * | 2019-11-01 | 2021-05-06 | GyanRx Sciences, Inc. | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors |
US20230129160A1 (en) * | 2020-01-08 | 2023-04-27 | Cantero Therapeutics, Inc. | Processes for preparing triazole glycolate oxidase inhibitors |
WO2022002131A1 (zh) * | 2020-06-30 | 2022-01-06 | 苏州恩华生物医药科技有限公司 | 5-((1,2,3,4-四氢异喹啉-7-基)氨基)吡啶-2(1h)-酮衍生物及其应用 |
WO2022066933A1 (en) * | 2020-09-24 | 2022-03-31 | Chinook Therapeutics Canada, Inc. | Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof |
CN114478210A (zh) * | 2022-02-26 | 2022-05-13 | 江苏壹药新材料有限公司 | 一种7-氯萘-2-甲醛的合成方法 |
WO2023170024A1 (en) * | 2022-03-11 | 2023-09-14 | University Of Copenhagen | Camk2 modulators and their use in medicine |
GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US149223A (en) * | 1874-03-31 | Improvement in axles for vehicles | ||
DE2860722D1 (en) * | 1977-11-10 | 1981-08-27 | Beecham Group Plc | Triazolo-quinoline derivatives, processes for their preparation and their pharmaceutical use |
DE2757929A1 (de) * | 1977-12-24 | 1979-07-05 | Boehringer Sohn Ingelheim | Neue pyrido-eckige klammer auf 1,2-a eckige klammer zu -v-triazolo- eckige klammer auf 4,5-d eckige klammer zu pyrimidinone, deren salze und verfahren zu deren herstellung |
JPS5519292A (en) * | 1978-07-24 | 1980-02-09 | Beecham Group Ltd | Benzopyranotriazoles*their manufacture and medical composition containing them |
DE2966444D1 (en) * | 1978-07-24 | 1984-01-05 | Beecham Group Plc | Benzopyranotriazoles, preparation of these compounds and pharmaceutical composition containing them |
US4431660A (en) * | 1979-06-11 | 1984-02-14 | Merck & Co., Inc. | (4'-Biphenylyloxy and-thio-oxy)-3-hydroxy-3-pyrroline-2,5-diones and a method of treating calcium oxalate renal lithiasis therewith |
US4349561A (en) * | 1979-11-05 | 1982-09-14 | Merck & Co., Inc. | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
IL61897A (en) * | 1980-01-19 | 1984-01-31 | Beecham Group Ltd | Benzopyrano(2,3-d)-v-triazoles,their production and pharmaceutical compositions containing them |
EP0032821B1 (en) * | 1980-01-19 | 1985-04-10 | Beecham Group Plc | Substituted benzopyranotriazoles |
NZ199139A (en) * | 1980-12-13 | 1985-01-31 | Beecham Group Ltd | Benz(phenoxyalkoxy)-9-oxo-1h,9h-benzopyrano-(2,3-d)-v-triazoles |
US4431652A (en) | 1980-12-29 | 1984-02-14 | Merck & Co., Inc. | 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis |
US4428956A (en) * | 1980-12-29 | 1984-01-31 | Merck & Co., Inc. | 4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis |
JPS57158788A (en) * | 1981-03-03 | 1982-09-30 | Beecham Group Ltd | Novel compound, manufacture and medicinal composition containing same |
US5326776A (en) * | 1992-03-02 | 1994-07-05 | Abbott Laboratories | Angiotensin II receptor antagonists |
EP1390353A1 (en) | 2001-04-27 | 2004-02-25 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
JP4075357B2 (ja) * | 2001-11-15 | 2008-04-16 | 宇部興産株式会社 | 4,5−ジ置換−1,2,3−トリアゾール及びその製造法 |
EP1569646A2 (en) * | 2002-12-13 | 2005-09-07 | Smithkline Beecham Corporation | Piperidine derivatives as ccr5 antagonists |
GB0329214D0 (en) * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
GB0603891D0 (en) | 2006-02-27 | 2006-04-05 | Syngenta Ltd | Novel herbicides |
WO2011140296A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Triazoles as inhibitors of fatty acid synthase |
MX2014014710A (es) | 2012-06-20 | 2015-03-04 | Hoffmann La Roche | Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar). |
KR101537296B1 (ko) * | 2012-10-26 | 2015-07-17 | 삼성전자 주식회사 | 반도체 나노결정 및 그 제조방법 |
TW201418242A (zh) * | 2012-10-26 | 2014-05-16 | Du Pont | 作為除草劑之經取代的*** |
JP2017095366A (ja) * | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
US20200262794A1 (en) * | 2015-12-07 | 2020-08-20 | Wake Forest University Health Sciences | Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones |
CN105541796B (zh) * | 2016-03-03 | 2017-11-14 | 武汉工程大学 | 一种nh‑1,2,3‑***联吡啶化合物的合成方法 |
CN105669569B (zh) * | 2016-03-03 | 2017-12-12 | 武汉工程大学 | 一种nh‑1,2,3‑***化合物的合成方法 |
US11384055B2 (en) * | 2017-12-29 | 2022-07-12 | Biomarin Pharmaceutical Inc. | Glycolate oxidase inhibitors for the treatment of disease |
PE20220901A1 (es) * | 2019-06-19 | 2022-05-30 | Biomarin Pharm Inc | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades |
-
2018
- 2018-12-28 US US16/958,511 patent/US11384055B2/en active Active
- 2018-12-28 IL IL297788A patent/IL297788A/en unknown
- 2018-12-28 MX MX2020006414A patent/MX2020006414A/es unknown
- 2018-12-28 EP EP18840000.6A patent/EP3732167A2/en active Pending
- 2018-12-28 CA CA3086401A patent/CA3086401A1/en active Pending
- 2018-12-28 CN CN201880090533.XA patent/CN111788187A/zh active Pending
- 2018-12-28 WO PCT/US2018/067784 patent/WO2019133770A2/en active Application Filing
- 2018-12-28 CN CN202310936652.5A patent/CN117069713A/zh active Pending
- 2018-12-28 JP JP2020535997A patent/JP7344878B2/ja active Active
- 2018-12-28 SG SG11202005807QA patent/SG11202005807QA/en unknown
- 2018-12-28 KR KR1020207022038A patent/KR20200112860A/ko not_active Application Discontinuation
- 2018-12-28 IL IL297802A patent/IL297802A/en unknown
- 2018-12-28 PE PE2020000860A patent/PE20201500A1/es unknown
- 2018-12-28 AR ARP180103914A patent/AR114070A1/es unknown
- 2018-12-28 CN CN202310936668.6A patent/CN117126152A/zh active Pending
- 2018-12-28 TW TW112107812A patent/TW202340155A/zh unknown
- 2018-12-28 AU AU2018395275A patent/AU2018395275A1/en active Pending
- 2018-12-28 MA MA051418A patent/MA51418A/fr unknown
- 2018-12-28 CN CN202310936523.6A patent/CN117069712A/zh active Pending
- 2018-12-28 CN CN202310936618.8A patent/CN117126151A/zh active Pending
- 2018-12-28 TW TW107147699A patent/TWI811282B/zh active
- 2018-12-28 BR BR112020013073-7A patent/BR112020013073A2/pt unknown
- 2018-12-28 CN CN202310936604.6A patent/CN117024420A/zh active Pending
-
2020
- 2020-06-18 IL IL275496A patent/IL275496A/en unknown
- 2020-06-25 CL CL2020001742A patent/CL2020001742A1/es unknown
- 2020-07-13 MX MX2022016463A patent/MX2022016463A/es unknown
- 2020-07-13 MX MX2022016434A patent/MX2022016434A/es unknown
- 2020-07-13 MX MX2022016427A patent/MX2022016427A/es unknown
- 2020-07-13 MX MX2022016415A patent/MX2022016415A/es unknown
- 2020-07-13 MX MX2022016422A patent/MX2022016422A/es unknown
-
2022
- 2022-05-23 US US17/751,136 patent/US20230079913A1/en active Pending
- 2022-05-23 US US17/751,144 patent/US20230089374A1/en active Pending
-
2023
- 2023-08-04 JP JP2023127874A patent/JP2023159181A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022016463A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
MX2021015874A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
EP4219713A3 (en) | Products and compositions | |
BR112016029041A2 (pt) | terapia de combinação com inibidores de glutaminase | |
PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
EA201791874A1 (ru) | Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение | |
MX2016003486A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
MX2017011277A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
MX2021011507A (es) | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. | |
MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
MX2020007586A (es) | Proceso de fabricacion de moduladores de somatostatina. | |
MX2021009555A (es) | Ligandos de pseudocinasa tyk2. | |
MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
MX2022005563A (es) | Ligandos de la pseudoquinasa tyk2. | |
MX2021013602A (es) | Inhibidores de jak. | |
MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
MX2022006176A (es) | Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2. | |
MX2022000712A (es) | Moduladores de nlrp3. | |
MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. |